Next Phase Newsletter

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

With less than a month left until RESI Boston September 2023, LSN is very excited to announce the list of 50+ finalist companies who will be participating in the Innovator’s Pitch Challenge (IPC) at our next conference at the Boston Park Plaza on Monday, September 18, followed by 2 days of virtual partnering on September 19-20!

Over 50 companies representing therapeutics, medical devices, diagnostics, digital health, and R&D / life science tools across the globe will be delivering a live pitch followed by a Q&A session with a panel of investors and industry experts. In addition to the live pitching, all companies will be presenting a poster showcasing their technology in the exhibit hall. We look forward to featuring all of these high-caliber innovations at the upcoming RESI!

Below are the participating companies. If you are interested in seeing these pitches and engaging in one-on-one partnering with over 600 attendees expected to attend, you can register here!

We are also actively recruiting investors and industry experts to participate in our IPC sessions as judges reviewing the companies and asking them questions validating their company and technology. If interested, please reach out to research@lifesciencenation.com for more information.

RESI Boston September Pitch Companies

By Candice He, Vice President of Business Development, Global Investment Strategist, LSN

We are excited to announce an exclusive workshop that will be a pivotal highlight of the RESI Boston Conference, happening from September 18-20. Join us and unlock the door to non-dilutive grant funding for your early-stage health innovations

Workshop Topic: Leveraging NIH’s Non-Dilutive Grant Funding

Date: September 18th Time: 11:00 AM ET Location: Boston Park Plaza

Workshop Description

The NIH helps US-based small businesses in their early stages by offering over $1.3 billion in R&D funding through various programs. Small businesses can use NIH funding to generate proof-of-concept data, de-risk their innovation, and attract partners and investors to commercialize their innovation. We support a range of high-impact technologies, such as research tools, diagnostics, digital health, drugs, medical devices, and more. The NIH’s grants do not require equity and can provide the initial funding you need to translate your scientific innovations from an idea to a product. On this panel, representatives of the National Institute on Aging and the National Institute of General Medical Sciences will discuss how to apply for NIH funding, NIH-funded programs and entrepreneurial hubs which support founders across the nation, and unique priority areas in disease areas like Alzheimer’s disease and dementia.

Meet the Panelists

We are happy to introduce the speakers from the NIH who will provide a comprehensive overview of the relevant programs and their requirements:

Eddie Billingslea Small Business Strategy Coordinator National Institute on Aging	Joshua HOOKS Program Officer National Institute on Aging	Rajesh Kumar Program Officer National Institute on Aging

Get Registered for RESI Boston Conference

This workshop is an opportunity for attendees registered for the RESI Boston September conference. If you haven’t already, register now for RESI to gain access to this invaluable workshop and a multitude of other networking and learning opportunities.

Visit the NIA Exhibit Table

While at the conference, we encourage you to explore the NIA exhibit table. Engage with the experts directly, discover more about NIH Small Business Programs, and explore the vast potential for collaboration and innovation in aging-related research and development.

National Institute on Aging (NIA)

The National Institute on Aging’s (NIA) Small Business Programs manage the largest source of early-stage funding for aging-related R&D. With an annual budget of over $140 million, NIA provides R&D grants to small businesses through the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs. Our mission is to develop interventions that prevent or treat Alzheimer’s disease (AD) and AD-related dementias, and we are committed to driving innovation in this critical field.

Join us at the RESI Boston Conference on September 18th at 11:00 AM ET and embark on a transformative journey into the world of non-dilutive grant funding, innovation, and collaboration. Register to meet NIA team and 300+ life science investors to unlock the potential of your health innovations.

Should you have any questions or require further information, please don’t hesitate to contact us at resi@lifesciencenation.com.

We look forward to welcoming you to this exciting event!

By Dennis Ford, Founder and CEO of Life Science Nation, Creator of the RESI Conference Series

RESI Boston September will feature the Family Office BioForum, for both sourcing assets and identifying syndication partners bridging the gap between family offices and investment opportunities within the life sciences sector. The Family Office BioForum will feature an open-to-the-public Family Office Panel as part of the RESI program and an invitation-only luncheon discussing early-stage investment topics, including souring technology assets, identifying syndicate opportunities, and finding the right investment funds.

As the life sciences sector continues to burgeon with groundbreaking discoveries, therapies, and technologies, the need for early capital injection becomes ever more pronounced. The Family Office BioForum is a convergence point where family offices can simultaneously identify promising startups and collaborate with other like-minded investors.

The Power of Syndication

Syndication has emerged as a dynamic strategy in the investment landscape, offering distinct advantages to family offices and entrepreneurs seeking funding. Family offices can diversify risk and share due diligence efforts by joining forces with other investors in a syndicate. This collaborative approach allows investors to tap into a broader range of investment opportunities and capitalize on their combined expertise. Conversely, entrepreneurs benefit from access to a syndicate’s collective knowledge and resources, expediting fundraising and enhancing their chances of securing the necessary funds.

The Family Office Factor

Family offices are known for their long-term investment outlook and commitment to fostering meaningful impact. With a mission to preserve and grow their wealth across generations, family offices are uniquely positioned to contribute to the life sciences sector. Their involvement goes beyond monetary support; it encompasses mentorship, guidance, and a vested interest in the success of the ventures they invest in. The Global Family Office BioForum acknowledges this distinctive role and seeks to create an environment where family offices can connect with like-minded syndicate partners and explore transformative investment opportunities.